OOIR: Observatory of International Research

Papers

(The H4-Index of npj Breast Cancer is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Author Correction: Characterization and spatial distribution of infiltrating lymphocytes in medullary, and lymphocyte-predominant triple negative breast cancers	496
Discerning the impact of ctDNA detection on patient decision-making in early-stage breast cancer	251
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab	192
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment	165
Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors	118
Effects of socioeconomic status and race on survival and treatment in metastatic breast cancer	117
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab	102
Immunotherapy for early triple negative breast cancer: research agenda for the next decade	95
Race-related host and microbe transcriptomic signatures in triple-negative breast cancer	89
Biological correlates associated with high-risk breast cancer patients identified using a computational method	88
GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer	83
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer	83
C/EBPβ isoform-specific regulation of migration and invasion in triple-negative breast cancer cells	73
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients	73
International survey on invasive lobular breast cancer identifies priority research questions	66
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial	63
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC	61
Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events	55
Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer	55
The search for CDK4/6 inhibitor biomarkers has been hampered by inappropriate proliferation assays	53
Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4/6 Inhibitor resistance in breast cancer cell lines	52
Breastfeeding attributable fraction of triple negative breast cancer in the US	50
Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer	50
Loss of the extracellular matrix glycoprotein EMILIN1 accelerates Δ16HER2-driven breast cancer initiation in mice	48
Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer	48

Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer	47
Temporal evolution of breast cancer brain metastases treatments and outcomes	45
Deep learning radiomics based prediction of axillary lymph node metastasis in breast cancer	42
International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)	41
Antibody-drug conjugates for treating early-stage breast cancer: current use, anticipated evolutions	40
Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer	40
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models	40
A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study)	38
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases	37
Survival outcomes after omission of surgery for ductal carcinoma in situ	35